Publications

Birtamimab PRASINEZUMAB CORAMITUG (PRX004)Other

Birtamimab

2023

Birtamimab plus standard of care in light chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
Birtamimab plus standard of care in light chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

Morie A. Gertz, Adam D. Cohen, Raymond L. Comenzo, Efstathios Kastritis, Heather J. Landau, Edward N. Libby, Michaela Liedtke, Vaishali Sanchorawala, Stefan Schönland, Ashutosh D. Wechalekar, Jeffrey A. Zonder, Giovanni Palladini, Jackie Walling, Spencer Guthrie, Christie Nie, Carol Karp, Yuying Jin, Gene G. Kinney, Giampaolo Merlini

American Society of Hematology (ASH), Blood Journal; DOI: 10.1182/blood.2022019406; 2023

2022

In-Hospital Mortality in Amyloid Light Chain Amyloidosis: Analysis of the Premier Healthcare Database
In-Hospital Mortality in Amyloid Light Chain Amyloidosis: Analysis of the Premier Healthcare Database

Tiffany P. Quock, Anita D’Souza, Michael S. Broder, Katalin Bognar, Eunice Chang, Marian H. Tarbox
Journal of Comparative Effectiveness Research; DOI:10.2217/CER.2022.0185; December 2022

2021

Work Outcomes Among Patients with Light Chain Amyloidosis: Findings from Three Patient Cohorts
Work Outcomes Among Patients with Light Chain Amyloidosis: Findings from Three Patient Cohorts

Avery A. Rizio, Kristen L. McCausland, Michelle K. White, Tiffany P. Quock

Patient Related Outcome Measures; DOI:10.2147/PROM.S337676; 2021

2019

Associations between Health-Related Quality of Life and Self-Reported Emergency Room Department Visits and Inpatient Hospitalizations: Insights from a Secondary Data Analysis of Patients with Light-Chain (AL) Amyloidosis
Associations between Health-Related Quality of Life and Self-Reported Emergency Room Department Visits and Inpatient Hospitalizations: Insights from a Secondary Data Analysis of Patients with Light-Chain (AL) Amyloidosis

McCausland KL, Rizio AA, White MK, Bayliss MS, Quock TP

PharmacoEconomics; 1-9; 22 February 2019
Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States
Untangling the Clinical and Economic Burden of Hospitalization for Cardiac Amyloidosis in the United States

Quock TP, Yan JT, Tieu R, D’Souza A, Broder MS

ClinicoEconomics and Outcomes Research; (11) 431-439; 2019

2018

Cardiac biomarkers and health-related quality of life in patients with light chain (AL) amyloidosis
Cardiac biomarkers and health-related quality of life in patients with light chain (AL) amyloidosis

McCausland KL, Quock TP, Rizio AA, Bayliss MS, White MK, Guthrie SD, Sanchorawala V

British Journal of Haematology; 22 November 2018
Epidemiology of AL amyloidosis: a real-world study using US claims data
Epidemiology of AL Amyloidosis: A Real-World Study Using US Claims Data

Quock TP, Yan JT, Chang E, Guthrie S, Broder MS

Blood Advances; 2(10): 1046-1053; 2018
Mortality and healthcare costs in Medicare beneficiaries with AL amyloidosis
Mortality and Healthcare Costs in Medicare Beneficiaries with AL Amyloidosis

Quock TP, Chang E, Munday JS, D’Souza A, Gokhale S, Yan JT

Journal of Comparative Effectiveness; 7(11); 25 October 2018
Real-World Healthcare Utilization and Costs in Amyloid Light-Chain Amyloidosis: A Real-World Study Using US Claims Data
Real-World Healthcare Utilization and Costs in Amyloid Light-Chain Amyloidosis: A Real-World Study Using US Claims Data

Quock TP, Yan JT, Chang E, Guthrie S, Broder MS

Journal of Comparative Effectiveness Research; DOI: 10.2217/cer-2017-0100; 2 February 2018
Treatment Tolerability in Patients with Immunoglobulin Light-Chain Amyloidosis
Treatment Tolerability in Patients with Light Chain Amyloidosis

Rizio AA, White MK, McCausland KL, Quock TP, Guthrie SD, Yokota M, Bayliss MS

American Health and Drug Benefits; 11(8); 2018

2017

Light Chain (AL) Amyloidosis: The Journey to Diagnosis
Light Chain (AL) Amyloidosis: The Journey to Diagnosis

McCausland KL, White MK, Guthrie SD, Quock TP, Finkel M, Lousada I, Bayliss MS

Patient 2017; DOI: 10.1007/s40271-017-0273-5; 4 August 2017

2016

2A4 Binds Soluble and Insoluble Light Chain Aggregates from AL Amyloidosis Patients and Promotes Clearance of Amyloid Deposits by Phagocytosis
2A4 Binds Soluble and Insoluble Light Chain Aggregates from AL Amyloidosis Patients and Promotes Clearance of Amyloid Deposits by Phagocytosis

Mark Renz, Ronald Torres, Philip J. Dolan, Stephen J. Tam, Jose R. Tapia, Lauri Li, Joshua R. Salmans, Robin M. Barbour, Paul J. Shughrue, Tarlochan Nijjar, Dale Schenk, Gene G. Kinney, Wagner Zago

Amyloid; DOI: 10.1080/13506129.2016.1205974; 2016
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction

Morie A. Gertz, Heather Landau, Raymond L. Comenzo, David Seldin, Brendan Weiss, Jeffrey Zonder, Giampaolo Merlini, Stefan Schönland, Jackie Walling, G.G. Kinney, Martin Koller, Dale B. Schenk, Spencer D. Guthrie, Michaela Liedtke

Journal of Clinical Oncology; DOI:10.1200/JCO.2015.63.6530; 8 February 2016
Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody
Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody

Morie A. Gertz, Heather J. Landau, Brendan M. Weiss

American Journal of Hematology; DOI: 10.1002/ajh.24563; 21 October 2016

2012

AL Amyloid Imaging and Therapy with a Monoclonal Antibody to a Cryptic Epitope on Amyloid Fibrils
AL Amyloid Imaging and Therapy with a Monoclonal Antibody to a Cryptic Epitope on Amyloid Fibrils

J.S. Wall, S.J. Kennel, A. Williams, T. Richey, A. Stuckey, Y. Huang, S. Macy, R. Donnell, R. Barbour, P. Seubert, D. Schenk

PLoS ONE; 7(12):e52686; 2012

2011

Generation and Characterization of anti-AA Amyloid-Specific Monoclonal Antibodies.
Generation and Characterization of anti-AA Amyloid-Specific Monoclonal Antibodies

J.S. Wall, S.J. Kennel, T. Richey, A. Allen, A. Stuckey, D.T. Weiss, R. Barbour, P. Seubert, A. Solomon, D. Schenk

Frontiers of Immunology; DOI:10.3389/fimmu.2011.00032; 2011

PRASINEZUMAB

2018

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease A Randomized Clinical Trial
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease A Randomized Clinical Trial
Joseph Jankovic, MD; Ira Goodman, MD; Beth Safirstein, MD; Tonya K. Marmon, DrPH; Dale B. Schenk, PhD; Martin Koller,MD, MPH;Wagner Zago, PhD; Daniel K. Ness, DVM, PhD; Sue G. Griffith, MD, PhD, MRCP; Michael Grundman, MD, MPH; Jay Soto, BS; Susanne Ostrowitzki, MD, PhD; Frank G. Boess, PhD; Meret Martin-Facklam, PhD; Joseph F. Quinn, MD; Stuart H. Isaacson, MD; Omid Omidvar, MD; Aaron Ellenbogen, DO; Gene G. Kinney, PhD
JAMA Neurology; DOI: 10.1001/jamaneurol.2018.1487, Published online June 18, 2018.

2016

First-in-human assessment of PRX002, an anti–α-synuclein monoclonal antibody, in healthy volunteers
First-in-human assessment of PRX002, an anti–α-synuclein monoclonal antibody, in healthy volunteers
Dale B. Schenk, Martin Koller, Daniel K. Ness, Sue G. Griffith, Michael Grundman, Wagner Zago, Jay Soto, George Atiee, Susanne Ostrowitzki, and Gene G. Kinney
Movement Disorders, DOI: 10.1002/mds.26878 (2016)

PRX004

2016

Novel Conformation-specific Monoclonal Antibodies Against Amyloidogenic Forms of Transthyretin
Novel Conformation-specific Monoclonal Antibodies Against Amyloidogenic Forms of Transthyretin

Jeffrey N. Higaki, Avi Chakrabartty, Natalie J. Galant, Kevin C. Hadley, Bradley Hammerson, Tarlochan Nijjar, Ronald Torres, Jose R. Tapia, Joshua Salmans, Robin Barbour, Stephen J. Tam, Ken Flanagan, Wagner Zago & G. G. Kinney
Amyloid, DOI:10.3109/13506129.2016.1148025 (2016)

OTHER

2013

Vascular alterations in PDAPP mice following anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities (ARIA)
Vascular alterations in PDAPP mice following anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities (ARIA)W. Zago, S. Schroeter, T. Guido, K. Khan, P. Seubert, T. Yednock, D. Schenk, K.M. Gregg, D. Games, F. Bard, G.G. Kinney
Alzheimers Dementia 9, S105–S115 (2013)

2012

Neutralization of soluble synaptotoxic Aß species by antibodies is epitope specific
Neutralization of soluble synaptotoxic Aß species by antibodies is epitope specificW. Zago, M. Buttini, T.A. Comery, C. Nishioka, P. Seubert, D. Games, F. Bard, D. Schenk, G.G. Kinney
Journal of Neuroscience, 32:2696-2702 (2012)
Sustained levels of antibodies against Aß in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice
Sustained levels of antibodies against Aß in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic miceF. Bard, M. Fox, S. Friedrich, P. Seubert, D. Schenk, G.G. Kinney, T. Yednock
Exp Neurol., 238:38-43 (2012)

2010

Structural Correlates of Antibodies Associated with Acute Reversal of Amyloid β-related Behavioral Deficits in a Mouse Model of Alzheimer Disease
Structural Correlates of Antibodies Associated with Acute Reversal of Amyloid β-related Behavioral Deficits in a Mouse Model of Alzheimer DiseaseG. Basi, H. Feinberg, F. Oshidari, J. Anderson, R. Barbour, J. Baker, T.A. Comery, L. Diep, D. Gill, K. Johnson-Wood, A. Goel, K. Grantcharova, M. Lee, J. Li, A. Partridge, I. Griswold-Prenner, N. Piot, D. Walker, A. Widom, M.N. Pangalos, P. Seubert, J.S. Jacobsen, D. Schenk, W.I. Weis
Journal of Biological Chemistry 285(5):3417-3427 (2010)

2005

Aβ42 Immunization in Alzheimer’s Disease Generates Aβ N-Terminal Antibodies
Aβ42 Immunization in Alzheimer’s Disease Generates Aβ N-Terminal AntibodiesM. Lee, F. Bard, K. Johnson-Wood, C. Lee, K. Hu, S. Griffith, R. Black, D. Schenk, P. Seubert
Ann. Neurol. 58, 430-435 (2005)

1999

Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouseD. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vazquez, C. Vendevert, S. Walker, M. Wogulis, T. Yednock, D. Games, P. Seubert
Nature, 400, 173-177 (1999)